ALFA Finder| Revenue growth | 7% YoY for FY26; Q4 accelerated to 10%. |
|---|---|
| Margins | FY26 EBITDA margin at 21.2%; targeting steady annual expansion. |
| Demand visibility | Strong momentum in Top 10 brands contributing 58% of revenue. |
| Management confidence | High; citing sharper strategic execution and outperforming market growth. |
Growth
FY26 Revenue grew 6.9% to ₹2,872 Mn; Operational PAT rose 19% YoY to ₹446 Mn.
Outlook
Targeting 1.5x IPM growth and 100-150 bps annual margin improvement beyond FY27.
Risks
Regulatory changes, currency fluctuations, and competitive pressures in core therapy segments.
Earnings Call filed with NSE, NSE: JAGSNPHARM. Summary written with AI assistance from the document.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹216.67
- Market cap
- ₹1,429 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 31.4×Sector 43.8×
- Promoter holding
- 68.81%-0.24% QoQ
- FII holding
- 2.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹964 Mn (+29%, Aequitas consolidated); standalone revenue ₹814 Mn (+9.3%), EBITDA margin 22.7%, PAT ₹126 Mn flat. H1 standalone PAT +10.3%.
Jagsonpal Pharmaceuticals Results Update
Jagsonpal reported Q2 FY27 consolidated revenue up 29% to ₹964 Mn, with standalone revenue up 9.3%. Standalone H1 PAT grew 10.3% and cash stood at ₹1,347 Mn.
Jagsonpal Pharmaceuticals Q2 FY27 Results: Net Profit ₹12.6 Cr, Up 0.0% YoY
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹81.4 Cr (+9.3% YoY) and net profit of ₹12.6 Cr (+0.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹12.6 Cr · +0.0% YoY
Jagsonpal Pharmaceuticals Board Meeting Date
Jagsonpal Pharmaceuticals Ltd will hold a Board Meeting on October 28, 2026, to consider and approve the company's unaudited financial results for the quarter ended September 30, 2026.
Jagsonpal Pharmaceuticals Other Announcement
Jagsonpal Pharmaceuticals Ltd filed its quarterly shareholding pattern statement in compliance with SEBI Regulation 31(1)(b).
Jagsonpal Pharmaceuticals Acquisition
Jagsonpal Pharmaceuticals has completed the acquisition of the Wellness Portfolio from Group Pharmaceuticals Limited, following the fulfilment of all conditions precedent in the agreement.
- From
- Group Pharmaceuticals Limited